Developing life-changing gene therapies for fatal and debilitating diseases of the central nervous system

Voyager Therapeutics (NASDAQ: VYGR) is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system. Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The Company’s pipeline is focused on severe CNS diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University of Massachusetts Medical School.

Year Invested: 2014
Location: Cambridge, Mass.

Recent News

May 9, 2017
Voyager Therapeutics Reports First Quarter 2017 Financial Results and Corporate Highlights

May 4, 2017
Voyager Therapeutics to Host First Quarter 2017 Financial Results and Corporate Highlights Conference Call

April 25, 2017
Voyager Therapeutics Announces Additional Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease

Read More News

Associated Team Members

Mark Levin

Perry Karsen
Venture Partner

Philip Reilly, M.D., J.D.
Venture Partner